ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir (BIVIR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00799760
Recruitment Status : Terminated (Just Terminated for the end of the pandemia)
First Posted : December 1, 2008
Last Update Posted : March 19, 2012
Sponsor:
Collaborators:
Hoffmann-La Roche
GlaxoSmithKline
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

November 28, 2008
December 1, 2008
March 19, 2012
December 2008
November 2009   (Final data collection date for primary outcome measure)
RT-PCR for influenza A virus in nasal secretion [ Time Frame: 2 days ]
Same as current
Complete list of historical versions of study NCT00799760 on ClinicalTrials.gov Archive Site
  • Time to resolution of influenzal illness Severity of illness [ Time Frame: 14 days ]
  • Severity of illness [ Time Frame: 14 Days ]
  • Adverse event (graded on a four -point scale:mild-moderate- severe-life threatening) [ Time Frame: 14 days ]
  • Compliance to antiviral treatment [ Time Frame: 14 days ]
  • Number of persons with influenza illness in households contact [ Time Frame: 14 days ]
  • Evaluation of restricted activity (requirement for additional health car) [ Time Frame: 14 days ]
  • Frequency of and need for antibiotic treatment of influenza (otitis media, bronchitis, sinusitis, and pneumonia ) [ Time Frame: 14 days ]
  • Frequency of resistance to antiviral drugs [ Time Frame: 14 days ]
Same as current
Not Provided
Not Provided
 
Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir
Evaluation of Combination Therapy With Oseltamivir and Zanamivir Versus Monotherapy in the Treatment of Virologically Confirmed Influenza in Primary Care a Randomises Double Blind Controlled Trial Study
In order to prevent the high mortality due to an hypothetic pandemic caused by a newly emerging influenza A virus, antiviral drugs are seen as essential requirements for control of initial influenza outbreaks.Two antivirals are available for the treatment oseltamivir and zanamivir. Emergence of Oseltamivir resistance has been recently reported. . It appeared opportune to assess the efficacy and safety of biotherapy of neuraminidase inhibitors ,will be investigated by a randomized, placebo controlled, double blind study in France, during the next winter season . This study will be conducted in 300 centres of primary care with 900 adults with a virologically suspected influenza A infection. Individuals will be randomized to 1 of the 3 treatment groups: oseltamivir +zanamivir, or oseltamivir+placebo or placebo +zanamivir.The primary judgment criteria will be the proportion of patients with negative RT PCR negative in nasal secretions at Day 2.

In the near future, a pandemic caused by a newly emerging influenza A virus has been predicted by the WHO. In order to prevent the high mortality due to the pandemic, antiviral drugs are seen as essential requirements for control of initial influenza outbreaks.

Zanamivir (GSK) and Oseltamivir (Roche) are stockpiled by the French government in the setting of pre-pandemic plan. In France, Zanamivir and Oseltamivir are both registered for the prophylactic and therapeutic use against influenza A.

Previous studies have shown that neuraminidase inhibitors (oseltamivir and zanamivir, based treatment) are associated with shorter illness duration and resulted in significant decrease of viral load in the nasal secretions.

In Winter season 2007-2008 the presence of oseltamivir-resistant viruses circulating in the community in several European countries is in marked contrast to the previous winter seasons, when oseltamivir resistance was detected in <1% of circulating strains from . Patients infected by viruses with neuraminidases carrying these mutations, didn't present unusual disease syndromes.

Although zanamivir and oseltamivir are both issued from the same class ,a combination of these two neuraminidase inhibitors could reduce the duration and severity of acute influenza and the incidence of secondary complications, reduce the spread of influenza, and the frequency of neuraminidase inhibitors mutations. An evaluation of the combination of oseltamivir and zanamivir versus zanamivir with placebo versus oseltamivir associated with placebo in the treatment of a virologically suspected influenza in primary care will be investigated in a randomised double blind placebo controlled trial study in France during the winter season 2008-2009.

Primary outcome measure:

Evaluate viral efficacy after 2 days of biotherapy oseltamivir and zanamivir versus zanamivir with placebo versus oseltamivir associated with placebo.

Patients and methods:

Randomised double blind, placebo controlled multicenter trial conducted during the influenza season 2008-2009 Arm 1: oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days Arm 2: oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 days Arm 3: oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days.

Schedule:

D0: rapid test diagnostic for influenza A urine pregnancy test for women inclusion /randomisation initiation of treatment D2:nasal sample for influenza RNA RTPCR D5:End of treatment D7:medical evaluation (follow up evaluation) D14:nurse call (clinical evaluation)

Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Gastric Influenza
  • Drug: oseltamivir + zanamivir
    oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days
    Other Name: experimental Arm
  • Drug: oseltamivir + zanamivir's placebo
    oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 day
    Other Name: Active comparator Arm
  • Drug: oseltamivir's placebo + zanamivir
    oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
    Other Name: active comparator arm
  • Experimental: 1
    oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days
    Intervention: Drug: oseltamivir + zanamivir
  • Active Comparator: 2
    oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 days
    Intervention: Drug: oseltamivir + zanamivir's placebo
  • Active Comparator: 3
    oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
    Intervention: Drug: oseltamivir's placebo + zanamivir

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
541
900
November 2010
November 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Influenza season declared
  • Subjects aged>18 years presenting within 36h documented of onset influenza illness
  • Who have fever >38°C
  • who present at least on of the following respiratory symptoms( cough, sore throat, nasal symptoms)
  • and one of the following constitutional symptoms(headache, myalgia, sweats and or chills or fatigue)
  • positive rapid diagnostic test for influenza A
  • who have giving written informed consent prior to enrollment
  • Patient examined before the inclusion
  • able to complete a questionnaire.

Exclusion Criteria:

  • Influenza Vaccination in the 12 months prior the beginning of the study
  • Patient unable to use diskhaler of Zanamivir
  • Asthma, Chronic bronchitis,
  • Woman with a positive urine pregnancy test
  • Clearance of creatinine< 30 ml/min Chronic renal disease
  • History of depression, psychiatric disorders
  • oseltamivir or zanamivir hypersensibility
  • patient treated by oseltamivir or zanamivir or amantadine 14 days before
  • Non member of the social security or CMU
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT00799760
P060209
AOM 08209 ( Other Identifier: French Ministry )
2008-004026-16 ( EudraCT Number )
Yes
Not Provided
Not Provided
Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris
  • Hoffmann-La Roche
  • GlaxoSmithKline
Principal Investigator: Catherine LEPORT, MD, PhD Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris
November 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP